

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

**(1) DELAY IN PUBLICATION OF AUDITED CONSOLIDATED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021;
(2) PUBLICATION OF UNAUDITED CONSOLIDATED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021; AND
(3) DATE OF BOARD MEETING**

DELAY IN PUBLICATION OF AUDITED CONSOLIDATED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

The board (the “**Board**”) of directors (the “**Directors**”) of Shandong Weigao Group Medical Polymer company Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) hereby announces that the recent outbreak of COVID-19 Omicron and the measures introduced to contain the spread of it in Weihai, Hong Kong and certain regions of China have imposed restraints on the Company’s auditor Deloitte Touche Tomatsu (the “**Auditor**”) to carry out audit procedures in relation to the financial results of the Group for the year ended 31 December 2021. Consequently, the auditing processes have been severely impacted and as a result are behind the original schedule. With respect to this limitation facing the execution of the auditing processes that would cause the Auditor to expect of additional time for completing their audit work, it is anticipated that the Company will not be able to publish the audited consolidated annual results announcement of the Group for the year ended 31 December 2021 (the “**Results Announcement**”) on or before 31 March 2022 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

* For identification purpose only

PUBLICATION OF UNAUDITED CONSOLIDATED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

To ensure that the shareholders and potential investors of the Company will continue to receive sufficient information regarding the business operation and financial position of the Group in order to make informed investment decisions, the Board has decided to publish the unaudited consolidated annual results announcement of the Group for the year ended 31 December 2021 on 29 March 2022.

DATE OF BOARD MEETING

The Directors hereby announce that, a meeting of the Board will be held on Tuesday, 29 March 2022, for the purposes of, among other matters, considering and approving the announcement of the unaudited consolidated annual results of the Group for the year ended 31 December 2021 and its publication, and considering the recommendation of a final dividend, if any. The Company will make further announcement(s) as and when appropriate in relation to the latest development in the completion of the audit processes and the expected date of publishing the Results Announcement. The Company will publish the Results Announcement which have been agreed with the Auditor in accordance with Rule 13.49 of the Listing Rules as soon as practicable.

By Order of the Board

Shandong Weigao Group Medical Polymer Company Limited

Long Jing

Chairman

Weihai, Shandong, the PRC, 24 March 2022

As at the date hereof, the Board comprises:

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive Director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Mr. Lian Xiaoming (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Mingzhong (*Independent non-executive Director*)

Mrs. Wang Jinxia (*Independent non-executive Director*)